Colorectal Neoplasms - Economics
Research News and Information

Monday, November 23, 2009

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

22 Sep 2009 BACKGROUND: Although colorectal cancer screening is cost-effective, it requires a considerable net investment by governments or insurance companies. If screening was cost saving, governments and insurance companies might be more inclined to invest ... Read more...

Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications?

5 Sep 2009 OBJECTIVE: To assess whether knowledge of insurance implications influenced uptake of genetic testing by participants in a research study of the causes of colorectal cancer. DESIGN, SETTING AND PARTICIPANTS: Analysis of uptake of genetic testing by ... Read more...

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

30 Aug 2009 BACKGROUND: The objective of this study was to examine the cost effectiveness of using a pharmacogenetic test for uridine diphosphate glycosyltransferase 1A1*28 (UGT1A1*28) variant homozygosity before administering irinotecan to patients with ... Read more...

Latest indexed articles for 'Colorectal Neoplasms - Economics'

These are the very latest articles for this heading:

• Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. 22 Sep 2009
• Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? 5 Sep 2009
• Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. 30 Aug 2009
• Making sense of differing bowel cancer screening guidelines. 15 Aug 2009
• Challenges and opportunities for use of cost-effectiveness analysis. 5 Aug 2009
• Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. 5 Aug 2009
• What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea? 5 Jul 2009
• Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. 29 Jun 2009
• Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? 29 Jun 2009
• Modeling the cost-effectiveness of colorectal cancer screening: policy guidance based on patient preferences and compliance. 28 Jun 2009
• Ireland's recommended colorectal cancer screening programme will not get extra government funding. 21 Jun 2009
• Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. 31 May 2009
• Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden. 30 May 2009
• Deciding to operate for low-grade colorectal dysplasia in ulcerative colitis: how much does the colon cost, how much is it worth? 30 May 2009
• The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. 30 May 2009
• Cost implications of new treatments for advanced colorectal cancer. 13 May 2009
• CT colonography to screen for colorectal cancer and aortic aneurysm in the Medicare population: cost-effectiveness analysis. 29 Apr 2009
• Using quality improvement techniques to increase colon cancer screening. 29 Apr 2009
• A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy. 22 Apr 2009
• The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing. 30 Mar 2009

See a longer list of these articles.

Technical information about 'Colorectal Neoplasms'

Definition: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Descriptor UI: D015179

Alternative terms: Colorectal Neoplasms; Colorectal Tumors; Colorectal Tumor; Tumor, Colorectal; Tumors, Colorectal; Neoplasms, Colorectal; Colorectal Neoplasm; Neoplasm, Colorectal; Colorectal Carcinoma; Carcinoma, Colorectal; Carcinomas, Colorectal; Colorectal Carcinomas; Colorectal Cancer; Cancer, Colorectal; Cancers, Colorectal; Colorectal Cancers;

Related Mesh Headings: Genes, DCC; Genes, MCC;

Allowable Qualifiers: blood; blood supply; cerebrospinal fluid; chemically induced; classification; complications; congenital; diagnosis; diet therapy; drug therapy; economics; embryology; enzymology; ethnology; etiology; genetics; history; immunology; metabolism; microbiology; mortality; nursing; epidemiology; parasitology; pathology; physiopathology; prevention & control; psychology; radiography; radionuclide imaging; radiotherapy; rehabilitation; secondary; secretion; surgery; therapy; ultrastructure; urine; veterinary; ultrasonography; chemistry; virology;

Tree Number: C04.588.274.476.411.307; C06.301.371.411.307; C06.405.249.411.307; C06.405.469.158.356; C06.405.469.491.307; C06.405.469.860.180;

History Note: 89

Technical Notes: a clinical entity: not a synonym for COLONIC NEOPLASMS + RECTAL NEOPLASMS; coord IM with histol type of neopl (IM); GENES, DCC (for "Deleted in Colorectal Cancer") & GENES, MCC (for "Mutated in Colorectal Cancer") are available: see MeSH scope notes and annotations there